Ionis Pharmaceuticals (IONS) Stock Highlights

35.63 | +0.11%

2024-12-21 01:58:03

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Statistics

Range Today

35.05 36.4

Volume Today 4.06M

Range 1 Year

33.33 54.44

Volume 1 Year 336.98M

Range 3 Year

28.25 54.44

Volume 3 Year 869.53M

Range 10 Year

19.59 86.58

Volume 10 Year 3.52B

Highlights

Market Capitalization 6.19B (mid)

Floating Shares 147.81M

Current Price 35.63

Price To Earnings -15.55

Price To Revenue 6.51

Price To Book 8.82

Earnings Per Share -2.48

Payout Ratio 0%

Performance

Latest +0.11%

1 Month +5.26%

3 Months -16.56%

6 Months -11.83%

1 Year -28.98%

3 Years +11.03%

5 Years -42.08%

10 Years -44.53%

Benchmarks

Market Capitalization

28 / 368

Gross Profits

269 / 278

Total Revenue

23 / 300

Total Rank

326 / 368

Free Cashflow

342 / 352

Performance 5 years

161 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.